Predicting drug efficacy for cognitive deficits in schizophrenia

Schizophrenia Bulletin

Volumn 31, Issue 4, 2005, Pages 830-853

  Hagan, Jim J ^a   Jones, Declan N C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cognition; Efficacy; Prediction; Schizophrenia; Translational strategy

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHLORPROMAZINE; CLOPENTHIXOL; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H3 RECEPTOR ANTAGONIST; ILOPERIDONE; LAMOTRIGINE; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SEROTONIN 4 AGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TOLCAPONE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ALERTNESS; ATTENTION; BRAIN FUNCTION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; LEARNING; MAZE TEST; MEDICAL LITERATURE; MEMORY; META ANALYSIS; PASSIVE AVOIDANCE; PREPULSE INHIBITION; PRIORITY JOURNAL; PROBLEM SOLVING; RECOGNITION; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TASK PERFORMANCE; TREATMENT OUTCOME; VERBAL MEMORY; VISUAL MEMORY; WISCONSIN CARD SORTING TEST; WORKING MEMORY;

ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; LEARNING; MEMORY; PREDICTIVE VALUE OF TESTS; PROBLEM SOLVING; PROGNOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 26444457491     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbi058     Document Type: Conference Paper

References (208)

1. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH-MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004;72:5-9.
2. Heinrichs RW. The primacy of cognition in schizophrenia. Am Psychol 2005;60:229-242.
3. Pelletier M, Achim AM, Montoya A, Lal S, Lepage M. Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis. Schizophr Res 2004;74:233-252.
4. Buchanen RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bull 2005;31:5-19.
5. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000;14:1-21.
6. Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 2004;72:21-28.
7. Sharma T. Impact on cognition of the use of antipsychotics. Curr Med Res Opin 2002;18:S13-17.
8. Sitskoorn MM, Aleman A, Ebisch SJH, Appels MCM, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res 2004;71:285-295.
9. Hoff AL, Svetina C, Maurizio AM, Crow TJ, Spokes K, DeLisi LE. Familial cognitive deficits in schizophrenia. Am J Med Genet (Neuropsychiat Genet) 2005;133B:43-49.
10. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiat 2001;58:24-32.
11. Wexler BE, Nicholls SS, Bell MD. Instability of cognitive processing systems in schizophrenia. Schizophr Res 2004;71:513-514.
12. Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiat 2005;57:688-691.
13. Tuulio-Henriksson A, Partonen T, Suvisaari J, Haukka J, Lönnqvist J. Age of onset and cognitive functioning in schizophrenia. Brit J Psychiat 2004;185:215-219.
14. Joyce E. Origins of cognitive dysfunction in schizophrenia: clues from age at onset. Brit J Psychiat 2005;186:93-95.
15. Green MF, Kerns RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophrenia Bull 2000;26:119-136.
16. Green MF, Kerns SR, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004;72:45-51.
17. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiat 1996;153:321-330.
18. Hyman SE, Fenton WS. What are the right targets for psychopharmacology? Science 2003;299:350-351.
19. Arnsten AFT. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 2004;174:25-31.
20. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favourable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 2004;174:17-24.
21. 1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004;174:3-16.
22. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 2004;174:45-53.
23. Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet 2005;42:193-204.
24. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression and neuropathology: on the matter of their convergence. Mol Psychiatr 2005;10:40-68.
25. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000;28:53-67.
26. Hakak Y, Walker JR, Li C, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. P Natl Acad Sci USA 2001;98:4746-4751.
27. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 2004;77:858-866.
28. Tkachev D, Mimmack ML, Ryan MM, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Mech Dis 2003;362:798-805.
29. MacDonald AW, Carter CS, Kernss JG, et al. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first episode psychosis. Am J Psychiat 2005;162:475-484.
30. Kaiser S, Foltz LA, George CA, et al. Phencyclidine-induced changes in rat cortical gene expression identified by microarray analysis: implications for schizophrenia. Neurobiol Dis 2004;16:220-235.
31. Nuechterlein KH, Barch DM, Gold JM, Goldbert TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004;72:29-39.
32. Braff DL, Saccuzzo DP. Effect of antipsychotic medication on speed of information processing in schizophrenic patients. Am J Psychiat 1982;139(9):1127-1130.
33. Daston PG. Effects of two phenothiazine drugs on concentrative attention span of chronic schizophrenics. J Clin Psychol 1959;15:106-109.
34. Gilgash CA. Effects of thorazine on Wechsler scores of adult catatonic schizophrenics. Psychol Rep 1957;3:561-564.
35. Medalia A, Gold J, Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsych 1988;3:249-271.
36. Mishara AL, Goldbert TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiat 2004;55:1013-1022.
37. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophrenia Bull 1990;3:477-499.
38. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiat 2001;158:176-184.
39. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology 2002;162:11-17.
40. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bull 1999;25:201-222.
41. Meltzer HY, McGurk SR. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia Bull 1999;25:233-255.
42. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophrenia Bull 2001;48:17-28.
43. Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kühn K-U. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacol 2005;30:381-390.
44. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuro-psychoph 2004;28:1213-1219.
45. Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog Neuro-psychoph 2004;28:659-665.
46. Kerns JG, Berenbaum H, Barch DM, Banich MT, Stolar N. Word production in schizophrenia and its relationship to positive symptoms. Psychiat Res 1999;87:29-37.
47. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatr Neurosci 2001;26:137-149.
48. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239-248.
49. Akdede BBK, Alptekin K, Kitis A, Arkar H, Akvardar Y. Effects of quetiapine on cognitive functions in schizophrenia. Prog Neuro-psychoph 2005;29:233-238.
50. Weickert TW, Goldbert TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of cognitive performance during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacol 2003;28:1491-1500.
51. Ellenbroek BA. Pre-attentive processing and schizophrenia: animal studies. Psychopharmacology 2004;174:65-74.
52. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001;156:234-258.
53. Braff DL, Geyer MA, Light GA, et al. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res 2001;49:171-178.
54. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001;156:117-154.
55. Weike AI, Bauer U, Hamm AO. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biol Psychiat 2000;47:61-70.
56. Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL. Modulation of the startle response and startle laterality in relatives of schizophrenia patients and schizotypal personality disordered subjects: evidence of inhibitory deficits. Am J Psychiat 2000;157:1660-1668.
57. Kumari V, Soni W, Sharma T. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiat 1999;156:1046-1051.
58. Kumari V, Soni W, Mathew VM, Sharma T. Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication. Arch Gen Psychiat 2000;57:609-614.
59. Kumari V, Soni W, Sharma T. Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. Schizophr Res 2002;55:139-146.
60. Leumann L, Feldon J, Vollenweider FX, Ludewig K. Effects of typical and atypical antipsychotic on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol Psychiat 2002;52:729-739.
61. Parwini A, Duncan EJ, Bartlett E, et al. Impaired prepulse inhibition of acoustic startle in schizophrenia. Biol Psychiat 2000;47:662-669.
62. Duncan EJ, Szilagyi S, Efferen TR, et al. Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia. Psychopharmacology 2003;167:63-71.
63. Duncan EJ, Szilagyi S, Schwartz MP, et al. Pre-pulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol. Psychiat Res 2003;120:1-12.
64. Hamm AO, Weike AI, Schupp HT. The effect of neuroleptic medication on prepulse inhibition in schizophrenia patients: current status and future issues. Psychopharmacology 2001;156:259-265.
65. Kumari V, Sharma T. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology 2002;162:97-101.
66. Mackeprang T, Kristiansen KT, Glenthoj BY. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. Biol Psychiat 2002;52:863-873.
67. Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuro-psychoph 2003;27:1071-1079.
68. Van den Buuse M, Garner B, Koch M. Neurodevelopmental animal models of schizophrenia: effects on prepulse inhibition. Curr Mol Med 2003;3:459-471.
69. Feifel D, Priebe K. Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. Biol Psychiat 2001;50:425-433.
70. Gartlon JE, Cilia J, Shilliam CS, Staveley SM, Dawson LA, Jones DNC. Brattleboro rats as a model of schizophrenia. J Psychopharmacol 2004;18:A56.
71. Depoortere R, Perrault G, Sanger DJ. Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain. Behav Pharmacol 1991;8:364-372.
72. Olivier B, Leahy C, Mullen T, et al. The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology 2001;156:284-290.
73. Ouagazzal AM, Jenck F, Moreau JL. Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity. Psychopharmacology 2001;156:273-283.
74. Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatr 2002;7:1039-1053.
75. Geyer MA, Wilkinson LS, Humby T, Robbins TW. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiat 1993;34(6):361-372.
76. Bakshi VP, Swerdlow NR, Braff DL, Geyer MA. Reversal of isolation rearing-induced deficits in prepulse inhibition by seroquel and olanzapine. Biol Psychiat 1998;43(6):436-445.
77. Cilia J, Reavill C, Hagan JJ, Jones DNC. Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats. Psychopharmacology 2001;156:327-337.
78. Cilia J, Hatcher PD, Reavill C, Jones DNC. Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats: an update. Psychopharmacology 2005;180(1):57-62.
79. Cilia J, Hill MW, Reavill C, Jones DNC. Reversal of isolation-rearing- induced PPI deficits by quetiapine and ziprasidone but not by haloperidol. J Psychopharmacol 2005;19(Suppl to 5):A12.
80. Ellenbroek BA. Animal models in the genomic era: possibilities and limitations with special emphasis on schizophrenia. Behav Pharmacol 2003;14:409-417.
81. Feifel D, Melendez G, Shilling PD. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacol 2004;29:731-738.
82. Simosky JK, Stevens KE, Adler LE, Freedman EF. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology 2003;165:386-396.
83. Maxwell CR, Liang Y, Weightman BD, et al. Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacol 2004;29:739-746.
84. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiat 1996;40:181-188.
85. Adler LE, Olincy A, Cawthra EM, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenic patients. Am J Psychiat 2004;161:1822-1828.
86. Arango C, Summerfelt A, Buchanan RW. Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiat 2003;160:2066-2068.
87. Nagamoto HT, Adler LE, McRae KA, et al. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Neuropsychobiology 1999;39:10-17.
88. Lubow RE. Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophrenia Bull 2005;31:139-153.
89. Barrett SL, Bell R, Watson D, King DJ. Effects of amisulpiride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol 2004;18(2):156-172.
90. Williams JH, Wellman NA, Geaney DP, Cowen PJ, Feldon J, Rawlins JNP. Reduced latent inhibition in people with schizophrenia: an effect of psychosis or its treatment. Brit J Psychiat 1998;172:243-249.
91. Moser PC, Hitchcock JM, Lister S, Moran PM. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 2000;33:275-307.
92. Weiner I, Gaisler I, Schiller D, Green A, Zuckerman L, Joel D. Screening of antipsychotic drugs in animal models. Drug Develop Res 2000;50:235-249.
93. Shadach E, Gaisler I, Schiller D, Weiner I. The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacol 2000;23:151-161.
94. Robbins TW. The 5-Choice Serial Reaction Time Task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 2002;163:362-380.
95. Harrison AA, Everitt BJ, Robbins TW. Central 5-HT depletion enhances impulsive responsing without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology 1997;133:329-342.
96. Shoaib M, Bizarro L, Stolerman IP. Impairments in a sustained attention task following dopaminergic, noradrenergic and glutamatergic receptor blockade in rats. J Psychopharmacol 2000;14(Suppl):A21.
97. Kolb B, Wilshaw IQ. Performance of schizophrenic patients on tests sensitive to left or right frontal temporal, or parietal function in neurological patients. J Nerv Ment Dis 1983;171:435-443.
98. Roberts AC, Robbins TW, Everitt BJ. The effects of intra-dimensional and extra-dimensional shifts on visual discrimination learning in humans and non-human primates. J Exp Psychol 1988;40B:321-341.
99. Birrell JM, Brown VJ. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 2000;20:4320-4324.
100. Brown VJ, Bowman EM. Rodent models of prefrontal cortical function. Trends Neurosci 2002;25:340-343.
101. Colacicco G, Welzl H, Lipp H-P, Wurbel H. Attentional set-shifting in mice: modification of a rat paradigm, and evidence for strain dependent variation. Behav Brain Res 2002;132:95-102.
102. 6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology 2005;online 10.1007/S00213-005-2261-z.
103. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catechol-O- methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 2004;24:5331-5335.
104. Reid L, Egerton A, McGregor S, Morris BJ, Pratt JA. Chronic intermittent PCP administration produces an attention set shifting deficit in the rat. J Psychopharmacol 2004;18(3):A55.
105. Rodefer JS, Murphy ER, Baxter MG. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 2005;21(4):1070-1076.
106. Rizos Z, Lovic V, Tenn CC, Kapur S, Fletcher PJ. Rats sensitized to amphetamine but not PCP show deficits in an attentional set-shifting task. Soc for Neurosci 2003;754:11.
107. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharm 2005;20:183-198.
108. Beninger RJ, Wasserman J, Zanibbi K, Charbonneau D, Mangels J, Beninger BV. Typical and atypical antipsychotic medications differentially affect two nondeclarative memory tasks in schizophrenic patients: a double dissociation. Schizophr Res 2003;61:281-292.
109. Lis S, Krieger S, Gallhofer B, Torre P, Mittoux A, Menard F. Sertindole is superior to haloperidol in cognitive performance in patients with schizophrenia: a comparative study. Eur Neuropsychopharm 2003;13(Suppl):S323- S324.
110. Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficits in schizophrenia: an open study. Acta Psychiat Scand 1997;95:40-43.
111. Rybakowski JK, Borkowska A. The effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia. Int J Psychiat Clin 2001;5(4):249-256.
112. Sumiyoshi T, Jayathilake K, Meltzer HY. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. Schizophr Res 2002;59:7-16.
113. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ. Modafinil improves cognition and attentional set-shifting in patients with chronic schizophrenia. Neuropsychopharmacol 2004;29:1363-1373.
114. Abdul-Monim Z, Reynolds GP, Neill JC. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol 2003;17:57-65.
115. Abdul-Monim Z, Reynolds GP, Neill JC. Olanzapine and clozapine but not the typical agent chlorpromazine, are effective in ameliorating a sub-chronic PCP induced cognitive deficit in the rat. Brit J Pharmacol 2003;1(3):055P available at www.pa2online.org.
116. Idris NF, Repeto P, Neill JC, Large CH. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat. Psychopharmacology 2005;179:335-348.
117. Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. Eur J Pharmacol 1995;281:241-250.
118. Pemberton DJ, Martin AJ, Jones DNC. Effect of haloperidol, clozapine, olanzapine and aripiprazole on delayed non-matching to position in rats. J Psychopharmacol 2003;17(3):A46.
119. Gemperle AY, McAllister KH, Olpe H-R. Differential effects of iloperidone, clozapine and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm. Psychopharmacology 2003;169:354-364.
120. Wolff MC, Leander JD. Comparison of the effects of antipsychotics on a delayed radial maze task in rats. Psychopharmacology 2003;168:410-416.
121. Didriksen M, Sams-Dodd F. Effects of haloperidol, clozapine and sertindole after chronic administration on cognitive behavior in rats using the delay non-match to position paradigm. Soc for Neurosci 1997;747:24.
122. Addy N, Levin ED. Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacol 2002;27:534-541.
123. Addy NA, Pocivavsek A, Levin ED. Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. Neuropharmacology 2005;30(6):1121-1127.
124. He J, Yang Y, Xu H, Zhang X, Li X. Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacol 2005; online doi 10.1038/sj.npp.1300757.
125. Rosengarten H, Quartermain D. The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-old rats. Prog Neuro-psychoph 2002;26:1047-1054.
126. Drago F, Contarino A, Marino R, et al. Effects of acute or chronic administration of risperidone on motor and sexual behaviour of male rats. Pharmacol Res 1997;35:17-25.
127. Ichihara K, Nabeshima T, Kameyama T. Effects of haloperidol, sulpiride and SCH 23390 on passive avoidance learning in mice. Eur J Pharmacol 1988;151:435-442.
128. Ninan I, Kulkarni SK. Clozapine-induced cognitive dysfunction in mice. Method Find Exp Clin 1996;18:367-372.
129. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 1988;31:47-59.
130. Besheer J, Short KR, Bevins RA. Dopaminergic and cholinergic antagonism in a novel-object detection task with rats. Behav Brain Res 2001;126:211-217.
131. Engelmann M, Wotjak CT, Landgraf R. Social discrimination procedure, an alternative method to investigate juvenile recognition abilities in rats. Physiol Behav 1995;58:315-321.
132. 1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology 2005; online 10.1007/s00213-005-2268-5.
133. Scheel-Krüger J. Comparison of typical and atypical neuroleptics in the Morris swim maze. Behav Pharmacol 1992;3(S1):18.
134. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze - a comparative study between novel and reference antipsychotics. Psychopharmacology 1996;124:126-133.
135. Didriksen M. Clozapine, olanzapine, and sertindole affect spatial learning and memory differentially in rats after chronic treatment. Schizophr Res 2000;41:246.
136. Terry AV, Hill WD, Parikh V, Evans DR, Waller JL, Mahadik SP. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology 2002;164:360-368.
137. Terry AV, Hill WD, Parikh V, Waller JL, Evans DR, Mahadik SP. Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning in rats. Neuropsychopharmacol 2003;28:300-309.
138. Jentsch JD. Preclinical models of cognitive dysfunction in schizophrenia: new avenue to addressing unmet needs. Clin Neurosci Res 2003;3:303-313.
139. Andersen JD, Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of d-serine. Neuropsychopharmacol 2004;29:1080-1090.
140. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuro-psychoph 2003;27:687-700.
141. Ellenbroek BA, Riva MA. Early maternal deprivation as an animal model for schizophrenia. Clin Neurosci Res 2003;3:297-302.
142. Flagstad P, Glenthoj BY, Didriksen M. Cognitive deficits caused by late gestational disruption of neurogenesis in rats: a preclinical model of schizophrenia. Neuropsychopharmacol 2005;30:250-260.
143. Lipska BK. A neonatal hippocampal disconnection model; testing a neurodevelopmental hypothesis of schizophrenia. Clin Neurosci Res 2003;3:283-287.
144. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 2005;5:1-6.
145. Stefani MR, Moghaddam B. Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res 2002;134:267-274.
146. Stefani MR, Moghaddam B. Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiat 2005;57:433-436.
147. Renato MR, Moghaddam B. Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res 2002;134:267-274.
148. Li Z, Kim CH, Ichikawa J, Meltzer HY. Effect of repeated administration of phencyclidine on spatial performance in an eight-arm radial maze with delay in rats and mice. Pharmacol Biochem Be 2003;75:335-340.
149. Tenn CC, Kapur S, Fletcher PJ. Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology 2005;180:366-376.
150. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. Long-term behavioural and neurodegenerative effects of perinatal phencyclidine administration implications for schizophrenia. Neuroscience 2001;107:535-550.
151. Wiseman-Harris L, Sharp T, Gartlon J, Jones DNC, Harrison PJ. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Pharmacol 2003;18:1706-1710.
152. de Lima NM, Laranja DC, Bromberg E, Roesler R, Schröder N. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 2005;156:139-143.
153. 6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - an effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004;47(2):195-204.
154. Grayson B, Neill JC. The effect of PCP on novel recognition in the rat. J Psychopharmacol 2004;18(3):A72.
155. Castner SA, Golman-Rakic PS, Williams GV. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology 2004;174:125.
156. Weed MR, Taffe MA, Polis I, et al. Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance. Cogn Brain Res 1999;8:185-201.
157. Katner SN, Davis SA, Kirsten AJ, Taffe MA. Effects of nicotine and mecamylamine on cognition in rhesus monkeys. Psychopharmacology 2004;175:225-240.
158. Nakahara K, Hayashi T, Konishi S, Mihashita Y. Functional MRI of macaque monkeys performing a cognitive set-shifting task. Science 2002;295:1532-1536.
159. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000;287:2020-2022.
160. 4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology 1999;142:78-84.
161. Jentsch JD, Redmond E, Elsworth JD, Taylor JR, Youngren KD, Roth RH. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997;277:953-955.
162. Varvel SA, Vann RE, Wise LE, Philbin SD, Porter JH. Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology 2002;160:182-191.
163. Kapur S, Wadenberg ML, Remington G. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can J Psychiat 2000;45(3):241-246.
164. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302(3):1129-1134.
165. (2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacol 2001;25(5):633-641.
166. 2 receptor occupancy and the behavioural effects of haloperidol in the male rat. Brit J Pharmacol 2002;137(Proc Suppl):129P.
167. 2 receptor occupancy and the behavioural effects of antipsychotics in the male rats. Soc for Neurosci 2003;798:6.
168. Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. a review of preclinical data. Psychopharmacology 2005;179:154-163.
169. Lynch G. AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 2004;4:4-11.
170. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets 2004;3:181-194.
171. Buccafusco JJ, Weiser T, Winter K, Klinder K, Ferry AV. The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. Neuropharmacology 2004;46:10-22.
172. Ingvar M, Ambros-Ingerson J, Davis M, et al. Enhancement by an ampakine of memory encoding in humans. Exp Neurol 1997;146:553-559.
173. Lynch G, Granger R, Ambros-Ingerson J, Davis CM, Kessler M, Scher R. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol 1997;145(1):89-92.
174. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharm 2001;21:484-487.
175. Robbins TW. Homology in behavioural pharmacology: an approach to animal models of human cognition. Behav Pharmacol 1998;9(7):509-519.
176. Dudchenko PA. An overview of the tasks used to test working memory in rodents. Neurosci Biobehav R 2004;28:699-709.
177. Dalley JW, Cardinal RN, Robbins TW. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav R 2004;28:771-784.
178. Braff DL, Light GA. Preattentional and attentional cognitive deficits as
179. Sarter M. Animal cognition: defining the issues. Neurosci Biobehav R 2004;28:645-650.
180. Thorpe CM, Jacova C, Wilkie DM. Some pitfalls in measuring memory in animals. Neurosci Biobehav R 2004;28:711-718.
181. Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part I. Psychopharmacology 1992;107(2-3):144-159.
182. Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part II. Psychopharmacology 1992;107(4):461-473.
183. 1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004;174:3-26.
184. 3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 2005;179:567-575.
185. 3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulated cortex. Neuropsychopharmacol 2003;28:839-849.
186. Martin LF, Kem WR, Freedman R. α-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 2004;174:54-64.
187. Bohme GA, Letchworth SR, Piot-Grosjean O, et al. In vitro and in vivo characterization of TC-1827, a novel brain α4β2 nicotinic receptor agonist with pro-cognitive activity. Drug Develop Res 2004;62:26-40.
188. Meneses A. 5-HT system and cognition. Neurosci Biobehav R 1999;23:1111-1125.
189. 1B receptor knockout mouse: selective facilitation/impairment depending on the cognitive demand. Learn Memory 2003;10:466-477.
190. 1B receptor in spatial and aversive learning in the rat. Neuropsychopharmacol 2003;28:1642-1655.
191. Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiat 2001;158(10):1722-1725.
192. 4 receptors. Neuropharmacology 1997;36:4-5.
193. 4 receptors. Neuropharmacology 2001;41:844-853.
194. 6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology 2001;158:114-119.
195. 6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacol 2004;29:93-100.
196. 6 receptors. Curr Drug Targets CNS Neurol Dis 2004;3:59-79.
197. A α5 receptors with cognition enhancing properties. J Med Chem 2004;47:5829-5832.
198. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 2004;174:45-53.
199. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004;25:618-625.
200. 3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Therapeut 2004;103:1-20.
201. 3 receptor antagonist. J Pharmacol Exp Ther 2005;313:176-190.
202. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 2004;174:32-38.
203. Tsai G, Ralph-Williams RJ, Martina M, et al. Gene knockout of glycine transporter 1: characterisation of the behavioural phenotype. P Natl Acad Sci USA 2004;101:8485-8490.
204. Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine on working memory by pre-treatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2005;179:303-309.
205. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 2004;174:39-44.
206. Simosky JK, Stevens KE, Freedman EF. A novel element of the mechanism of action of atypical antipsychotic drugs: clozapine and olanzapine activate α7 nicotinic receptors to produce improved inhibitory processing. Soc for Neurosci 2004;798:1.
207. Cropley J, Gibson V, Rourke C, Hatcher P, Jones DNC, Reavill C. Pharmacological profile of atypical antipsychotic drugs. J Psychopharmacol 2003;S17(3):A48.
208. Rourke C, Starr KR, Jones DNC. Effects of aripiprazole, olanzapine, risperidone and ziprasidone upon performance of rats in the rotarod test. J Psychopharmacol 2003;S17(3):A48.